Biogen (NASDAQ:BIIB) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $239.5 with a loss of -2.69 points or -1.11%. The net money flow was $48.8 million and the up/down ratio was 1.8. Approximately $109.69 million was the inflow in upticks and $60.89 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of -2.69%.The shares witnessed a block transaction with a net money flow of $50.38 million. The total money in uptick was $50.38 million and in downtick was $0 million with the up/down ratio reaching 0.
Biogen Inc. has lost 3.22% in the last five trading days and dropped 9.87% in the last 4 weeks. Biogen Inc. has dropped 5.01% during the last 3-month period . Year-to-Date the stock performance stands at -22.24%.
Currently the company Insiders own 0.32% of Biogen shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.8% . Institutional Investors own 92.85% of Biogen shares. During last six month period, the net percent change held by insiders has seen a change of -7.26%. . On the companys insider trading activities, Koppel Adam, officer (EVP, Strategy and Bus. Dev.) of Biogen Inc., unloaded 555 shares at an average price of $290 on June 6, 2016. The total amount of the transaction was worth $160,950, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Biogen (NASDAQ:BIIB) witnessed a decline in the market cap on Friday as its shares dropped 1.64% or 3.98 points. After the session commenced at $242.27, the stock reached the higher end at $242.27 while it hit a low of $238.2. With the volume soaring to 2,219,712 shares, the last trade was called at $238.21. The company has a 52-week high of $420.99. The company has a market cap of $52,180 million and there are 219,051,490 shares in outstanding. The 52-week low of the share price is $236.54.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.